Chemotherapy plus immunotherapy before surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is stage II to IIIB (N2) and can be surgically removed.
- Your tumor has a specific EGFR mutation (Ex19del or L858R) and your PD-L1 level is 1% or higher.
- You are 18 years or older and have not had any prior anti-cancer treatment for this cancer.
- You are in generally good health (ECOG score 0-1) and can tolerate surgery.
- You have a measurable tumor on a scan, and you can provide a tissue sample for biomarker testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.